Chief Development Officer
Melanie Morrison serves as Black Diamond’s Chief Development Officer overseeing Product Leadership, Program Management, Regulatory Affairs, and Clinical Operations. Melanie brings to Black Diamond over 20 years of experience driving organizational transitions from early to late stage clinical development and oversight of multiple oncology products throughout their lifecycle.
Prior to Black Diamond, Melanie was Senior Vice President, Program Management and Clinical Operations at Nuvation Bio, a clinical-stage oncology company, where she built and oversaw multiple groups within the Development organization in support of Nuvation Bio’s pipeline. Previously in her career, Melanie held Program and Clinical Operations leadership roles at such companies as Aduro Biotech and Immune Design, where she served as Product Team Leader, Clinical Operations leader, and Chief of Staff. Prior to its acquisition by Pfizer, Melanie was Vice President, Clinical Operations for Medivation. In this role, she oversaw the development and execution of clinical development plans, functional resourcing for a team of approximately 100 employees across the development organization, and budgeting for 40+ studies. Earlier in her career, Melanie was at Genentech in roles with increasing responsibility within the Clinical Operations and Project Management groups supporting Genentech’s oncology pipeline. She holds a Master of Science in Health Sciences from The George Washington University School of Medicine and Health Sciences and a Bachelor of Science from University of California, Davis. She holds numerous certifications in regulatory affairs, project management, clinical research management, and public health from such organizations as UC Berkeley, UC Santa Cruz, and University of North Carolina at Chapel Hill. Melanie is also an Executive Scholar in Leadership and General Management from the Kellogg School of Management.